Guangzhou Wondfo Biotech Co Ltd (300482) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Guangzhou Wondfo Biotech Co Ltd (300482) has a cash flow conversion efficiency ratio of 0.021x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥116.99 Million ≈ $17.12 Million USD) by net assets (CN¥5.56 Billion ≈ $813.67 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Guangzhou Wondfo Biotech Co Ltd (300482) total market value for the company's overall valuation and market capitalisation.
Guangzhou Wondfo Biotech Co Ltd - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Guangzhou Wondfo Biotech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Guangzhou Wondfo Biotech Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Guangzhou Wondfo Biotech Co Ltd ranked by their cash flow conversion efficiency. Explore 300482 cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Grupa Pracuj S.A.
WAR:GPP
|
0.138x |
|
Eerly Govt Ppty Inc
NYSE:DEA
|
0.020x |
|
Jiuzhitang Co Ltd
SHE:000989
|
0.027x |
|
Wangneng Environment Co Ltd
SHE:002034
|
0.073x |
|
Chongqing Taiji Industry Group Co Ltd
SHG:600129
|
0.112x |
|
Elbit Systems Ltd
TA:ESLT
|
0.081x |
|
Tellhow Sci-Tech Co Ltd
SHG:600590
|
0.050x |
|
AXWAY SOFTWARE EO 2
F:1XV
|
N/A |
Annual Cash Flow Conversion Efficiency for Guangzhou Wondfo Biotech Co Ltd (2011–2025)
The table below shows the annual cash flow conversion efficiency of Guangzhou Wondfo Biotech Co Ltd from 2011 to 2025. View today's stock price for Guangzhou Wondfo Biotech Co Ltd for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥5.47 Billion ≈ $800.95 Million |
CN¥463.04 Million ≈ $67.76 Million |
0.085x | +32.15% |
| 2024-12-31 | CN¥5.65 Billion ≈ $826.81 Million |
CN¥361.71 Million ≈ $52.93 Million |
0.064x | -23.90% |
| 2023-12-31 | CN¥4.61 Billion ≈ $675.26 Million |
CN¥388.19 Million ≈ $56.80 Million |
0.084x | -77.31% |
| 2022-12-31 | CN¥4.54 Billion ≈ $663.99 Million |
CN¥1.68 Billion ≈ $246.15 Million |
0.371x | +95.36% |
| 2021-12-31 | CN¥3.50 Billion ≈ $512.76 Million |
CN¥664.93 Million ≈ $97.30 Million |
0.190x | -46.50% |
| 2020-12-31 | CN¥2.99 Billion ≈ $438.06 Million |
CN¥1.06 Billion ≈ $155.38 Million |
0.355x | +181.66% |
| 2019-12-31 | CN¥2.46 Billion ≈ $360.06 Million |
CN¥309.86 Million ≈ $45.34 Million |
0.126x | +9.42% |
| 2018-12-31 | CN¥2.15 Billion ≈ $314.82 Million |
CN¥247.61 Million ≈ $36.23 Million |
0.115x | -18.89% |
| 2017-12-31 | CN¥1.19 Billion ≈ $174.13 Million |
CN¥168.85 Million ≈ $24.71 Million |
0.142x | +8.28% |
| 2016-12-31 | CN¥854.75 Million ≈ $125.08 Million |
CN¥112.01 Million ≈ $16.39 Million |
0.131x | -30.35% |
| 2015-12-31 | CN¥700.64 Million ≈ $102.53 Million |
CN¥131.81 Million ≈ $19.29 Million |
0.188x | -43.56% |
| 2014-12-31 | CN¥313.43 Million ≈ $45.86 Million |
CN¥104.47 Million ≈ $15.29 Million |
0.333x | -20.24% |
| 2013-12-31 | CN¥241.47 Million ≈ $35.33 Million |
CN¥100.91 Million ≈ $14.77 Million |
0.418x | +1.91% |
| 2012-12-31 | CN¥182.48 Million ≈ $26.70 Million |
CN¥74.84 Million ≈ $10.95 Million |
0.410x | +148.81% |
| 2011-12-31 | CN¥144.61 Million ≈ $21.16 Million |
CN¥23.83 Million ≈ $3.49 Million |
0.165x | -- |
About Guangzhou Wondfo Biotech Co Ltd
Guangzhou Wondfo Biotech Co.,Ltd, an in vitro diagnostics company, engages in the research and development, production, market, sale, and service of vitro diagnostic products in China. The company offers rapid test kits for COVID-19, drug of abuse, tumor, infectious disease, fertility, tumor marker, and sexually transmitted diseases; immunofluorescence platform for detecting cardiac, thyroid, rhe… Read more